Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection

This article was retracted on 08 April 2010

This article has been updated


For a wide variety of microbial pathogens, the outcome of the infection is indeterminate. In some individuals the microbe is cleared, but in others it establishes a chronic infection, and the factors that tip this balance are often unknown. In a widely used model of chronic viral infection, C57BL/6 mice clear the Armstrong strain of lymphocytic choriomeningitis virus (LCMV), but the clone 13 strain persists1,2. Here we show that the Armstrong strain induces a profound lymphopenia at days 1–3 after infection, but the clone 13 strain does not. If we transiently augment lymphopenia by treating the clone-13-infected mice with the drug FTY720 at days 0–2 after infection, the mice successfully clear the infection by day 30. Clearance does not occur when CD4 T cells are absent at the time of treatment, indicating that the drug is not exerting direct antiviral effects. Notably, FTY720 treatment of an already established persistent infection also leads to viral clearance. In both models, FTY720 treatment preserves or augments LCMV-specific CD4 and CD8 T-cell responses, a result that is counter-intuitive because FTY720 is generally regarded as a new immunosuppressive agent3. Because FTY720 targets host pathways that are completely evolutionarily conserved, our results may be translatable into new immunotherapies for the treatment of chronic microbial infections in humans.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: LCMV Armstrong but not clone 13 induces profound lymphopenia at days 2 and 3 after infection.
Figure 2: Low-dose short-term FTY720 treatment of clone-13-infected mice prevents the establishment of a persistent LCMV infection.
Figure 3: Low-dose short-term FTY720 treatment clears an established persistent clone 13 infection.

Change history


  1. Ahmed, R., Byrne, J. A. & Oldstone, M. B. Virus specificity of cytotoxic T lymphocytes generated during acute lymphocytic choriomeningitis virus infection: role of the H-2 region in determining cross-reactivity for different lymphocytic choriomeningitis virus strains. J. Virol. 51, 34–41 (1984)

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Matloubian, M., Concepcion, R. J. & Ahmed, R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056–8063 (1994)

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Kunzendorf, U., Ziegler, E. & Kabelitz, D. FTY720–the first compound of a new promising class of immunosuppressive drugs. Nephrol. Dial. Transplant. 19, 1677–1681 (2004)

    Article  CAS  Google Scholar 

  4. Chisari, F. V. & Ferrari, C. Hepatitis B virus immunopathology. Springer Semin. Immunopathol. 17, 261–281 (1995)

    Article  CAS  Google Scholar 

  5. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350–354 (2006)

    Article  ADS  CAS  Google Scholar 

  6. Folgori, A. et al. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut 55, 1012–1019 (2006)

    Article  CAS  Google Scholar 

  7. Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911–4927 (2003)

    Article  CAS  Google Scholar 

  8. Shiow, L. R. et al. CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440, 540–544 (2006)

    Article  ADS  CAS  Google Scholar 

  9. Mamalaki, C. et al. Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Dev. Immunol. 3, 159–174 (1993)

    Article  CAS  Google Scholar 

  10. Brinkmann, V. et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453–21457 (2002)

    Article  CAS  Google Scholar 

  11. Chiba, K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 108, 308–319 (2005)

    Article  CAS  Google Scholar 

  12. Kappos, L. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355, 1124–1140 (2006)

    Article  CAS  Google Scholar 

  13. Budde, K. et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13, 1073–1083 (2002)

    CAS  PubMed  Google Scholar 

  14. Pinschewer, D. D. et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164, 5761–5770 (2000)

    Article  CAS  Google Scholar 

  15. Moskophidis, D., Lechner, F., Pircher, H. & Zinkernagel, R. M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362, 758–761 (1993)

    Article  ADS  CAS  Google Scholar 

  16. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205–2213 (1998)

    Article  CAS  Google Scholar 

  17. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687 (2006)

    Article  ADS  CAS  Google Scholar 

  18. Brooks, D. G. et al. Interleukin-10 determines viral clearance or persistence in vivo . Nature Med. 12, 1301–1309 (2006)

    Article  CAS  Google Scholar 

  19. Matter, M., Odermatt, B., Yagita, H., Nuoffer, J. M. & Ochsenbein, A. F. Elimination of chronic viral infection by blocking CD27 signaling. J. Exp. Med. 203, 2145–2155 (2006)

    Article  CAS  Google Scholar 

  20. Brooks, D. G., Lee, A. M., Elsaesser, H., McGavern, D. B. & Oldstone, M. B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 205, 533–541 (2008)

    Article  CAS  Google Scholar 

  21. Ha, S. J. et al. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J. Exp. Med. 205, 543–555 (2008)

    Article  CAS  Google Scholar 

  22. Muller, S. et al. Role of an intact splenic microarchitecture in early lymphocytic choriomeningitis virus production. J. Virol. 76, 2375–2383 (2002)

    Article  CAS  Google Scholar 

  23. Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94–96 (1996)

    Article  ADS  CAS  Google Scholar 

  24. Cembrzynska-Nowak, M. Different antiviral activity and cell specificity of interferon preparations produced by mouse peritoneal cells at 37 degrees C and at 26 degrees C. Arch. Immunol. Ther. Exp. (Warsz.) 37, 499–502 (1989)

    CAS  Google Scholar 

  25. Merrill, A. H., Sullards, M. C., Allegood, J. C., Kelly, S. & Wang, E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36, 207–224 (2005)

    Article  CAS  Google Scholar 

Download references


We would like to thank R. Ahmed for his support and guidance during the project; D. Liotta for the use of his mass spectrometer; and the members of the Ahmed and the Altman laboratories for discussions. This work was supported by National Institute of Health grant numbers AI042373 (to J.D.A.) and 5F32AI062002 (M.P.-L.).

Author Contributions M.P.-L. originated and designed the project, analysed the results and co-wrote the manuscript with J.D.A. who also provided guidance and support throughout the project. N.B.M. performed viral load assays. S.T.P. measured S1P levels. P.A.R. was involved in preliminary experiments.

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Mary Premenko-Lanier or John D. Altman.

Supplementary information

Supplementary information

The file contains Supplementary Figures 1-7 with Legends. (PDF 2588 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Premenko-Lanier, M., Moseley, N., Pruett, S. et al. Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection. Nature 454, 894–898 (2008).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing